Loftyrock Investment
Loftyrock Investment is a venture capital firm established in 2021 and based in Seoul, South Korea. The company specializes in providing investment services in both venture capital and private equity. Loftyrock focuses on sectors characterized by technological breakthroughs and convergence, with particular attention to biotechnology and non-biotechnology industries. Through its investment activities, Loftyrock aims to support innovative companies and foster advancements in technology.
2 past transactions
Genedit
Series A in 2024
GenEdit Inc., established in 2016 and headquartered in Berkeley, California, specializes in developing innovative genome editing tools. The company's core technology is CRISPR/Cas9, which enables precise therapeutic gene editing. GenEdit has further advanced this field by creating the NanoGalaxy™ platform, a proprietary non-viral delivery system that efficiently transports CRISPR/Cas9 to target tissues, overcoming previous delivery challenges. This platform systematically screens a library of nanoparticles to ensure safer and more effective delivery, making therapeutic gene editing easier, faster, and more accurate than traditional methods. GenEdit's ultimate goal is to facilitate the cure of previously incurable genetic diseases by providing physicians with powerful tools for gene therapy.
Galux
Series A in 2022
Galux specializes in molecular design technology for discovering and developing novel drugs targeting incurable and rare diseases. Its AI-based platform integrates artificial intelligence, physics, and chemistry to design biomolecules, aiding healthcare professionals.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.